

CVC Working Group - Proposed COVID-19 Terminology


Update on Generic Concept for AstraZeneca and Janssen Vaccines

To expedite the process of creating a code, the AstraZeneca COVID-19 concept has been created under the most generic COVID-19 term (28531000087107 [Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)]). However, a more granular generic term for both the AstraZeneca and Janssen vaccines is recommended when it becomes available.

Based on discussions with clinical subject matter experts (Dr. Sarah Wilson, Public Health Ontario & NACI Member; Dr. Monika Naus, Medical Director, Communicable Diseases & Immunization Service & Medical Head, Immunization Programs & Vaccine Preventable Diseases at the BCCDC) and sources gathered (see list below), the AZ and Janssen vaccines are considered "viral vector" vaccines, specifically, "non-replicating viral vector" vaccines. Both use adenoviruses as the viral vector, however, they do not use the *same* adenovirus vector. There has not been a perceived use case for creating such granular generic concepts at the level of the specific adenovirus.

Therefore, we are proposing that the AZ and Janssen vaccines fall under a parent concept, "COVID-19 non-replicating viral vector" vaccine (see diagram).

COVID-19 Terminology Hierarchy



We have confirmed with Linda Parisien that a generic concept for this does not exist, and have been informed that the SNOMED International community is currently working on developing terminology for this group of vaccines. New concepts for COVID-19 vaccines are anticipated to be available within the coming weeks from SNOMED International. This is also where the COVID-19 mRNA generic concept was drawn from in December. Once an appropriate term becomes available, the CVC will adopt this term as the parent of the AZ and Janssen vaccines, assuming that the concept aligns with the recommendations we have gathered from subject matter experts.

Sources that were shared to inform this recommendation include:

- Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. *New England Journal of Medicine*. 2020 May 21;382(21):1969-73.
- NACI Global Vaccine Candidate Situational Awareness
- Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov*. 2020 May;19(5):305-6.
- Callaway E. The race for coronavirus vaccines: a graphical guide. *Nature*. 2020 Apr;580(7805):576.
- Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. *Clinical Immunology*. 2020 Nov 17:108634.